Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)

Citation
Damman K, Beusekamp JC, Boorsma EM, et al. Eur J Heart Fail 2020; epub ahead of press.